The emerging class of GLP-1 receptor agonist and GIP dual medications, such as tirzepatide, semaglutide, and the recently introduced retatrutide, represent significant progress in diabetes control. https://bpc157469128.blogspothub.com/42332256/tirzepatide-one-thorough-examination